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Summary 
Background: Clinical trials have demonstrated that trastuzumab, a recombinant 
monoclonal antibody against HER-2 receptor, significantly improves overall (OS) and 
disease-free survival (DFS) in women with HER2-positive (HER2+) early breast 
cancer, but long-term follow-up is required. 
Methods: HERA (BIG 1-01) is an international, multicenter, open label, phase III 
randomized trial involving 5102 women with HER2+ early breast cancer enrolled 
between December 2001 and June 2005. After completing all primary therapy, 
including surgery, chemotherapy and radiotherapy as indicated, patients were 
randomized to trastuzumab for 1 year, trastuzumab for 2 years, or observation. 
Primary endpoint is DFS, and analyses are intent-to-treat. After release of positive 
results in May 2005, 884 (over 50%) of patients assigned to observation selectively 
crossed over to receive trastuzumab. Hazard ratios (HRs) were estimated from Cox 
models, and survival curves were estimated by Kaplan-Meier method. Comparison of 
2 years versus 1 year of trastuzumab is based on 366-day landmark analyses. This 
study is registered with ClinicalTrials.gov, number NCT00045032. 
Findings: After 11 years of median follow up, random assignment to 1 year of 
trastuzumab significantly reduced the risk of a DFS event (HR 0·76, 95% CI 0·68–
0.·86)  and death (HR 0·74, 0·64–0·86) compared with observation. Two years of 
adjuvant trastuzumab did not improve outcome compared with one year of 
administration for DFS (HR 1·02, 0·89–1·17). Estimates of 10-year DFS for 
observation or 1 year or 2 years of trastuzumab were 62·5%, 69·3%, 68·5%, and 12-
year OS estimates were 72·9%, 79·4%, 79·5%, respectively. Cardiac toxicity 
4 
 
remained low and occurred mostly during the treatment phase. 
Interpretation: One year of adjuvant trastuzumab following chemotherapy for patients 
with HER2+ early breast cancer significantly improves long-term DFS and OS 
outcomes with 11 years of median follow up. Two years of trastuzumab had no 
additional benefit. 
Funding: Hoffman La Roche (Roche) 
Word count = 298 
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INTRODUCTION 
Fifteen to twenty percent of patients with early breast cancer have tumours that exhibit 
overexpression and/or amplification of the HER2 receptor/ oncogene, and the use of 
adjuvant trastuzumab (Herceptin®) is now standard of care for these patients. Four 
large randomised trials have clearly demonstrated that trastuzumab has a major 
impact in reducing recurrence and death in patients with this type of early breast 
cancer. The initial trials compared one year of trastuzumab treatment with a no 
trastuzumab control.1–3 Further follow up confirmed a persistent benefit of one year of 
treatment versus observation.4–7 The HERA (HERceptin Adjuvant) trial is unique in 
that it also included randomization of patients to two years of trastuzumab.  
Demonstration that two years of trastuzumab was not superior to one year of 
trastuzumab7 reinforced the use of one year of treatment as the standard of care. 
Long-term follow up of patients with HER2-positive breast cancer is important to better 
understand the true impact of this disease, the benefits of trastuzumab, and long-term 
cardiovascular safety. This paper reports the results of the comparison between 
observation, one and two years of trastuzumab at 11-years’ median follow up within 
the HERA study. 
MATERIALS AND METHODS 
Study design 
Between December 7, 2001 and June 20, 2005, a total of 5102 patients were 
randomised (in a 1:1:1 ratio) to one of the 3 arms of the HERA trial as previously 
reported.1 Methods used to generate the random allocation sequence, stratification 
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factors, type of randomization, approval of the protocol by local ethics committees at 
each hospital, the need for each patient to give signed informed consent, and open 
label design are described elsewhere.5 The comparison of the trastuzumab arms 
versus observation was based on the intent-to-treat (ITT) principle, after excluding 
three patients with no record of written informed consent (Figure 1 consort diagram). 
The comparison of 2 years versus 1 year of trastuzumab was based on a 12-month 
landmark analysis involving the 3105 women who remained alive and disease-free for 
at least 12 months (366 days) after randomization to one of the two trastuzumab 
arms.7 Written informed consent, central laboratory (Kassel, Germany) confirmation of 
locally assessed HER2-positive disease, and left ventricular ejection fraction (LVEF) 
≥ 55% after completion of all chemotherapy with or without radiotherapy (Figure 1) 
were required. Open-label trastuzumab was administered intravenously using the 
doses and schedule shown in Figure 1.  Adjuvant endocrine therapy for women with 
steroid hormone receptor positive cancers was administered concomitantly with and 
after trastuzumab according to local protocols. 
Follow-up procedures 
All patients adhered to the same schedule of follow-up visits, which required the 
recording of symptoms, side effects (graded according to the National Cancer Institute 
Common Toxicity Criteria [NCI-CTC] version 2·0), and findings on clinical examination 
every three months for the first two years from randomization, with hematologic and 
chemistry studies performed every six months. These assessments were scheduled 
to occur every six months for years 3 to 5 and then annually up to year 10. Annual 
chest radiography was required to year 5 and annual mammography to year 10. Study 
visits for individual patients continued for 10 years from randomization with full 
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recording of breast cancer recurrences, contralateral breast cancer and second 
primaries. Selected adverse events, such as cardiac endpoints, were also collected. 
For patients who were alive and disease-free at the 10-year visit, the calculation of 
DFS included the additional follow-up time reported beyond 10 years and deaths 
reported during the additional follow-up period were counted as DFS events.  
Cardiac monitoring and endpoints 
Cardiac monitoring in the trastuzumab and the observation arms included clinical 
assessments and measurements of left ventricular ejection fraction (LVEF) by either 
echocardiography or MUGA scanning at baseline, months 3, 6, 12, 18, 24, 30, 36, and 
annually thereafter up to 10 years from randomization. A primary cardiac endpoint was 
defined as New York Heart Association (NYHA) class III or IV toxicity, confirmed by a 
cardiologist, and a significant left ventricular ejection fraction (LVEF) drop of at least 
10 percentage points from baseline and to an absolute LVEF below 50%, or cardiac 
death. A secondary cardiac endpoint was defined as asymptomatic (NYHA class I) or 
mildly symptomatic (NYHA class II) with a significant LVEF drop of at least 10 
percentage points below baseline and to an absolute LVEF below 50% confirmed by 
repeat assessment. An algorithm was defined in the protocol prescribing delay or 
cessation of trastuzumab in response to cardiac endpoints. 
Endpoints and statistical considerations 
This analysis was a pre-planned final efficacy analysis of the HERA trial. The primary 
endpoint was disease-free survival (DFS) as described previously,1 with events 
ending DFS almost identical to those used to define invasive disease free survival 
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(IDFS) using STEEP criteria.8 Secondary endpoints included overall survival (OS), 
sites of first relapse, competing risk cumulative incidence analysis of breast cancer 
and non-breast cancer DFS events, and prospectively planned efficacy analyses by 
local assessment of steroid hormone receptor status of the primary tumour. 
 
Safety, particularly cardiac safety, was also a secondary endpoint. Safety populations 
were generally defined according to randomised assignment, except that 20 patients 
assigned to 1 year and 25 patients assigned to 2 years of trastuzumab who never 
received trastuzumab were allocated to the observation safety population. Two 
additional patients randomized to 2 years of trastuzumab who initially refused 
trastuzumab but chose to receive trastuzumab after the release of the study results 
are included in the observation safety population until the time they started 
trastuzumab. Adverse events were considered from the time of randomization. 
Adverse events, including cardiac endpoints, recorded after crossover to trastuzumab 
of patients in the observation arm were excluded. 
The updated comparison of 1 year of trastuzumab versus observation was based on 
1702 and 1697 patients enrolled in the two arms, respectively, using an intention-to-
treat analysis from the time of randomization. A total of 884 (52·1%) of the 1697 
patients in the observation arm selectively crossed over to receive trastuzumab after 
the release of the initial results of this and other trials in 2005,1,2 of whom 477 (54.0%) 
had hormone receptor positive disease and 407 (46.0%) had hormone receptor 
negative disease (data not shown). As previously described,5 the selective crossover 
improved outcomes for the observation arm in the intention-to-treat analysis, resulting 
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in an underestimation of the true trastuzumab treatment effect had there been no 
selective crossover.  
Log-rank tests for time-to-event endpoints provided two-sided P values. Kaplan–Meier 
curves are presented.9 Cox proportional hazards modelling was used to estimate 
unadjusted hazard ratios and 95 percent confidence intervals.10 The cumulative 
incidence of cardiac endpoints based on competing risks was calculated.11 Exploratory 
Cox modelling was performed to examine interactions between treatment assignment, 
hormone receptor status, and time on study. Time-varying covariate Cox modelling11 
was performed to explore the effect of selective crossover on the risk of a DFS event 
in the no trastuzumab control group.  
Updated trastuzumab comparison   
The comparison of 2 years versus 1 year of trastuzumab was based on a 12-month 
landmark analysis involving the 3105 women who remained alive and disease-free for 
at least 12 months (366 days) after randomization to one of the two trastuzumab arms.  
Role of the sponsor 
The study was conducted under the auspices of the Breast International Group (BIG) 
and involved the collaboration of 17 BIG groups, 9 other cooperative groups, 91 
independent centres, and the pharmaceutical sponsor, Roche, all of which were 
represented in the Steering Committee of the HERA trial. The study was designed by 
members of the Steering Committee. The database was maintained at the Breast 
European Adjuvant Study Team (BrEAST) Data Centre, Brussels, Belgium. For the 
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final analysis, the HERA Executive Committee, on behalf of the HERA Steering 
Committee, was responsible for the decision to publish and for the content of the 
manuscript. The pharmaceutical sponsor provided the drug, some site monitoring and 
financial support.  
RESULTS 
Patient population 
The cohorts for comparison were well balanced with respect to demographics and 
baseline disease characteristics including tumour size, nodal and hormone receptor 
status (Table 1). Overall 2571 (50·4%) of the patients had hormone receptor positive 
disease and 2528 (49·6%) had hormone receptor negative disease by local 
laboratory determination of hormone receptors. A total of 2370 (92·2%) of the 
hormone receptor positive cases received adjuvant endocrine therapy. Most patients 
received chemotherapy only postoperatively but in 563 (11·0%) preoperative 
neoadjuvant chemotherapy had been administered. Chemotherapy included an 
anthracycline for 4797 (94·1%) of the patients, and an anthracycline and taxane for 
1328 (26·0%) of the patients. Patients with node negative disease were eligible for 
enrolment if the pathological tumour size was larger than 1 cm, and 1646 (32·3%) of 
the patients had node-negative disease. Overall 2642 (51·8%) of the patients were 
49 years of age or younger at the time of study entry. Patients in the HERA study 
started trastuzumab at a median of 8·4 months (interquartile range [IQR] 7·1 – 9·6 
months) after initial diagnosis of breast cancer and a median of 89 days (IQR 46-112 
days) after completing all chemotherapy. 
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Comparison of trastuzumab versus observation 
In this final report, results for 1 year of trastuzumab (18 cycles median of q3weekly) 
versus observation were based on 1113 DFS events [1103 (99·1%) satisfied the 
STEEP criteria for IDFS events] and 725 of the patients had died (an OS event). A 
total of 884 (52·1%) of the observation arm patients received trastuzumab before a 
DFS event due to selective crossover after publication of the initial trial results. 
Despite this selective crossover, using an ITT analysis, the hazard ratio after 11 
years of median follow up was 0·76 (95% CI 0·68-0·86) for 1-year trastuzumab vs 
observation. The hazard ratio for 2-years trastuzumab (35 cycles median of q3 
weekly) vs observation was similar, 0·77 (95% CI 0·69-0·87). The 10-year DFS rate 
was 62·5%, 69·3% and 68·5% in the observation, 1-year trastuzmab and 2-years 
trastuzumab arms, respectively (Figure 2, Panel A). This corresponded to an 
absolute benefit of 6·8% and 6·0% in DFS at 10 years for 1-year trastuzumab and 2-
years trastuzumab compared to observation, respectively. Of note in interpreting the 
ITT analysis is the fact that about half of the follow-up time in the observation arm 
was accrued after selective crossover to trastuzumab. The annualized hazard rates 
for disease-free survival over time are shown in Figure S1 (appendix). The 
exploratory time-varying covariate Cox model showed that selective crossover was 
associated with a reduction in risk of a DFS event in the observation arm (hazard 
ratio 0·79, 95% CI 0·64-0·98) (Table S3; appendix). Selective crossover was 
associated with a numerically lower impact for the hormone receptor positive cohort 
(0·92, CI 0·70-1·22) than for the hormone receptor negative cohort (0·69, CI 0·53-
0·91) (Table S3; appendix); (interaction p-value=0·10) (Table S2; appendix).  
In the hormone receptor positive cohort, the hazard ratio (1-year trastuzumab vs 
observation) was 0·80 (95% CI 0·68-0·96) and the absolute benefit in 10-year DFS 
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rate was 5·6%. The 10-year DFS rates were 65·9%, 71·5% and 69·6% in the 
observation, 1-year trastuzumab and 2-years trastuzmab arms, respectively (Figure 
2, Panel B). In the hormone receptor negative cohort, the 10-year DFS rates were 
lower; 59·1%, 67·1% and 67·3% for the observation, 1-year trastuzumab and 2-years 
trastuzumab arms, respectively. The hazard ratio for 1-year trastuzumab vs 
observation was 0·73 (95% CI 0·62-0·85) and the absolute benefit in 10-year DFS rate 
was 8·0% (Figure 2, Panel C). Exploratory Cox models comparing trastuzumab (both 
1- and 2-years combined) versus observation indicated that time since randomization 
was significantly associated with treatment effect for both hormone receptor positive 
and negative populations. Hazard ratios for early DFS events (up to 24 months from 
randomization) were 0·63 (CI 0·52-0·77) for hormone receptor positive and 0·59 (CI 
0·50-0·70) for hormone receptor negative cohorts (Table S5; appendix).  
Corresponding hazard ratios for later DFS events (24 months or more after 
randomization) were 0·98 (CI 0·82-1·16) and 0·91 (0·76-1·09), respectively (Table S5; 
appendix). 
Subgroup analyses of DFS by nodal status are shown in Table S6 (appendix). As 
expected, DFS was worse for patients with higher numbers of positive axillary lymph 
nodes. In the 1-year trastuzumab arm, the 10-year DFS rates were 80·1% for the node 
negative cohort, 74·5% for the 1-3 positive nodes cohort, and 54·5% for the ≥ 4 
positive nodes cohort. The hazard ratios (1-year trastuzumab vs observation) were 
0·78, 0·64 and 0·82 in these cohorts, respectively. 
Table 2 shows the site of first DFS event. The cumulative incidence curves of the 
competing risk of a DFS event related to breast cancer and of a DFS event not related 
to breast cancer are shown in Figure 2 (Panels D, E and F). A lower numerical 
cumulative incidence of DFS events related to breast cancer was seen in the 
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trastuzumab arms compared to the observation arm for both the hormone receptor 
positive and negative cohorts. The cumulative incidence of breast cancer-related DFS 
events was numerically lower in the hormone receptor positive cohort, and with a 
smaller absolute decrease in the trastuzumab arms, as compared with the hormone 
receptor negative cohort. No numerical decrease in the incidence of non-breast cancer 
related DFS events was seen in either the hormone receptor positive or negative 
cohorts. While clinical benefit of trastuzumab was seen in both the hormone receptor 
positive and hormone receptor negative cohorts, the timing and rate of DFS events 
appears different between these cohorts (Figure 2, Panels E-F).  
As with DFS, the results for OS also demonstrated a robust and persistent 
improvement despite the impact of selective crossover (Figure 4, Panel D). The hazard 
ratio (1-year trastuzumab versus observation) for overall survival at 11 years of median 
follow up was 0·74 (95% CI 0·64-0·86). The 12-year OS rates were 72·9%, 79·4% 
and 79·5% in the observation, 1-year trastuzumab and 2-years trastuzumab arms, 
respectively. The absolute benefit in 12-year OS was 6·5% and 6·6% for 1-year 
trastuzumab and 2-years trastuzumab, respectively (Figure S3, Panel A; appendix).  
Considering OS in the hormone receptor positive cohort, the hazard ratio (1-year 
trastuzumab vs observation) was 0·81 (95% CI 0·65-1·00). The 12-year OS rates were 
76·2%, 80·9% and 80·5% in the observation, 1-year trastuzumab and 2-years 
trastuzumab arms, respectively (Figure S3, Panel B). In the hormone receptor 
negative cohort, the 12-year OS rates were lower; 69·6%, 77·9% and 78·6% for the 
observation, 1-year trastuzumab and 2-years trastuzumab arms, respectively. The 
hazard ratio for 1-year trastuzumab vs observation was 0·70 (95% CI 0·57-0·85) 
(Figure S3, Panel C).  
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Safety 
No new safety concerns have emerged since previous reports.5,7 More patients had 
at least one grade 3 or 4 adverse event in the trastuzumab groups than the observation 
group (Table S7; appendix). Primary cardiac endpoints were very rare in this study, 
which introduced trastuzumab after completing all chemotherapy and radiation 
therapy and required a post chemotherapy LVEF ≥ 55 prior to enrolment. There was 
no significant difference in the occurrence of primary cardiac endpoints between the 
two trastuzumab arms, although the rates were higher than in the observation arm 
(Table S7; Figure 3, Panel A). Secondary cardiac endpoints occurred more frequently 
in the 2-years trastuzumab arm than in the 1-year trastuzumab arm, largely because 
the event rate observed in both arms during the first year continued during the second 
year only in the 2-years trastuzumab arm (Figure 3). In both trastuzumab arms, there 
were few cardiac endpoints beyond the completion of trastuzumab treatment. There 
was no evidence of a noticeable number of cardiac endpoints occurring a long time 
(approximately 10 years) after randomization (Figure 3).      
Update of Trastuzumab Duration Comparison 
Compliance with randomised assignment of trastuzumab duration was generally 
good.7 The update of the landmark analysis comparison of 2 years versus 1 year of 
trastuzumab was based on 814 DFS events. There was no evidence of a long-term 
benefit of 2 years compared to 1 year of trastuzumab when administered as sequential 
treatment following chemotherapy, with a hazard ratio for DFS of 1·02 (95% CI 0·89 – 
1·17) (Figure S5, Panel A). The short-term separation in the DFS curves in the 
hormone receptor negative cohort was not significant. Here, the long-term hazard ratio 
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was 0·94 (95% CI 0·77 – 1·14) (Figure S5, Panel C). In the hormone receptor positive 
cohort, the hazard ratio was 1·10 (95% CI 0·91 – 1·34) (Figure S5, Panel B). 
DISCUSSION  
After 11 years of median follow-up, it remains clear that the use of 1 year of adjuvant 
trastuzumab significantly improves disease outcomes when given in addition to 
standard of care, including chemotherapy, in patients with HER2-positive early breast 
cancer. The relative risk of a DFS event is reduced by 24%, conferring an absolute 
benefit of 6.8% improvement in 10-year DFS in those women randomised to 1-year 
trastuzumab as compared to those in the observation arm. Further, a 6.5% absolute 
gain was found in overall survival at 12 years. As previously noted,5 since just over 
half the patients in the observation arm crossed-over to receive trastuzumab after 
release of the initial results of this trial, these estimates of absolute benefit are likely 
to be underestimates of the true benefit for patients. In fact, in the current analysis, 
selective crossover was associated with a 21% relative reduction in the risk of a DFS 
event in the observation arm, thus clearly attenuating the trastuzumab effect estimated 
by the ITT analysis. Furthermore, trastuzumab treatment effects were significantly 
greater during the first 24 months since randomization compared with later during 
follow up, a finding that may be partially attributable to crossover. 
Subgroup analysis by tumour hormone receptor status confirms two important 
observations. Firstly, despite overexpression of the HER2 oncogene, hormone 
receptor status remains a powerful determinant of disease outcome, with more 
recurrences and deaths in the women with hormone receptor negative disease even 
after 11 years’ median follow-up. Furthermore, the data suggest that the timing of 
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recurrences is different, with a higher initial rate of DFS events in the patients with 
hormone receptor-negative disease, although events still accumulate out to 10 years 
in both groups. Table 2 reports the sites of first recurrence, where it is clear that all 
sites of recurrence are slightly more common in patients with hormone receptor-
negative, HER2-positive breast cancer, with the exception of skeletal distant 
recurrence, in keeping with what has been previously seen in non HER2-positive 
disease. Secondly, there is no evidence that the efficacy of trastuzumab is different 
according to the hormone receptor status of the primary tumour. Numerically, the 
hazard ratio was smaller in those women with hormone receptor-positive disease 
(0·80 vs 0·73 for 1-year trastuzumab vs observation), but the difference is not 
significant and could be affected by the higher percent of hormone receptor-positive 
cases who could cross over due to lower risk of early relapses. Benefit is also seen in 
overall survival in both hormone receptor groups, where the corresponding hazard 
ratios for 1-year trastuzumab vs observation were 0·81 for hormone receptor-positive 
and 0·70 for hormone receptor-negative cohorts, respectively. 
In earlier reports, there was evidence of progressively smaller apparent benefits of 
one year of trastuzumab in intention-to-treat analyses previously reported at 2-year 
and 4-years’ median follow up.5 The DFS hazard ratio for 1-year trastuzumab versus 
observation has however been stable since 4-years median follow up, 0·76 (Figure 4, 
Panel A). The results demonstrate a robust and persistent improvement in DFS 
despite the impact of selective crossover (Figure 4). Interestingly, despite the 
increased tendency for patients with hormone receptor-positive disease to have 
relapsed later, the estimated hazard ratios for DFS benefit stabilised at around 4 years’ 
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follow-up in both the hormone receptor cohorts, suggesting a profound and permanent 
effect of one year of trastuzumab on micrometastatic disease.  
Considering overall survival in the women with hormone receptor-negative and 
hormone receptor-positive tumours separately, in all analyses of 1-year trastuzumab 
vs observation there were fewer deaths in those women with hormone receptor-
positive disease than hormone receptor-negative disease.  Approximately half of the 
women enrolled into the HERA trial had hormone receptor-positive disease, whereas 
the true proportion in an incident breast cancer population may be nearer 60%.12 Thus 
this difference in timing of events, particularly for overall survival, means that 
interpretation of more recent clinical trials of adjuvant therapy in this patient population 
may require more cautious analysis. If the true benefit in the majority population of 
hormone receptor-positive tumours takes longer to appear, earlier analyses of overall 
survival could result in false negative conclusions. 
This manuscript also includes an updated analysis of a unique feature of the HERA 
trial, namely addressing the duration question by randomising 1/3 of the patients to a 
longer, 2-year duration of trastuzumab. The earlier report found no advantage for the 
longer therapy, and this is confirmed with this more mature analysis. This has real 
clinical relevance – there is no evidence that subjecting women to longer therapy with 
trastuzumab is the way to further reduce the risk of relapse and death from HER2-
positive early breast cancer. Data from several studies, including those in the neo-
adjuvant and metastatic disease settings12-15 all indicate that greater anti-tumour 
activity is seen when combining two anti-HER2 agents, although the first report from 
the ALTTO study of the small molecule HER2 inhibitor lapatinib combined with one 
year of trastuzumab12, did not find a clinically meaningful benefit. The only other study 
18 
 
reporting outcomes for longer than one year’s duration of anti-HER2 therapy was the 
ExteNET study16. That study tested the benefit of one year of a small molecule pan-
HER2 tyrosine kinase inhibitor after one year of trastuzumab, and the design was 
altered during the study to report events at 2 years in all patients and thus does not 
have long-term outcome data comparable to that reported here for HERA.  
This updated analysis of the HERA study again indicates that there may be a 
temporary benefit in DFS in those patients with hormone receptor-negative disease 
randomised to 2 years of trastuzumab compared to 1 year of trastuzumab. This may 
well be the play of chance, but with other emerging data it does pose the hypothesis 
that there may be other ways to enhance the efficacy of this agent in the adjuvant 
setting. For women with hormone receptor-positive tumours, even when HER2 
overexpressing, at least 5 years of adjuvant endocrine therapy is standard of care. 
This study and others3,6 confirm that despite this prolonged anti-tumour therapy, 
trastuzumab gives clear additional benefit if given for one year, but once that is 
stopped, the tumours are generally still subjected to active anti-cancer, endocrine 
therapy. By contrast, for those patients whose tumours are hormone receptor-
negative, once the trastuzumab is stopped and systemic levels fall, there is no anti-
tumour therapy given. As we now realise that part of the efficacy of trastuzumab may 
be due to its ability to induce an immunologically mediated anti-tumour effect17, this 
raises the possibility that concurrent modulation of the immune system, rather than 
further treatment with an anti-HER2 agent, could be of benefit. One might further 
conjecture that the transient short-term benefit from additional trastuzumab beyond 1 
year is seen because the prolonged higher antibody levels maintain that immune 
recruitment, but to an insufficient degree to effectively eradicate microscopic disease.  
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In patients with hormone receptor-positive disease, the prolonged anti-endocrine 
therapy may mask the signal of any additional temporary benefit from immune 
enhancement. This would lead to the hypothesis that addition of agents that enhance 
the immune anti-tumoural effect during the first year of therapy could be of real benefit 
if given in conjunction with trastuzumab acting as the “recruiter” of that immune 
response. 
A further important finding from this 11-year analysis is the safety of adjuvant 
trastuzumab. The unique feature of HERA is that serial LVEF assessment up to 10 
years was performed in all patients, which provides more complete cardiac information 
compared to the other adjuvant trastuzumab trials. No new safety signals have 
emerged despite the prolonged follow-up, and, in particular, no signal of late cardiac 
problems, despite the aging by one decade of the cohort in follow up subjecting them 
to an increased risk of age related cardiac morbidity. For those women randomised to 
the 2-year trastuzumab arm, there are more low-level cardiac endpoints seen during 
treatment, which these patients will have experienced despite the lack of additional 
benefit compared with 1-year trastuzumab. However, it is reassuring that the 
frequency during the second year remained similar to that observed during the first 
year, with few cardiac endpoints reported beyond 2 years, and the evidence that those 
that do occur are mostly reversible.18  
 
The selective crossover of just over half of the control arm patients is a clear limitation 
of this later intention-to-treat analysis of the HERA trial, though it is likely to provide an 
underestimate of the long-term efficacy of adjuvant trastuzumab. The lack of access 
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to all the primary tumour samples also precludes exploratory translational analyses 
that could allow better understanding of the biology of those tumours that relapse 
despite the use of adjuvant trastuzumab, and thus facilitate development of additional 
therapeutic approaches that could be beneficial. 
In conclusion, long-term follow-up of practice-changing clinical trials, such as the 
HERA trial, is essential to inform doctors and patients about the full range of benefits 
and burdens associated with new widely-adopted treatments. This 11-year median 
follow up analysis confirms a 24% relative reduction in risk of a DFS event, and a 26% 
relative reduction in risk of death, with the addition of one year of adjuvant trastuzumab 
in women with HER2-positive early breast cancer. There is no evidence of additional 
benefit from a second year of trastuzumab, but some evidence of additional cardiac 
toxicity with longer duration treatment. These results have been stable over the last 
several years of additional follow up. The benefits of one year of adjuvant trastuzumab 
are substantial for both individual patients and breast cancer populations, and indeed 
may even be underestimated due to the crossover of half of the observation arm. The 
benefits are seen irrespective of node status and tumour steroid hormone receptor 
status, although the absolute benefits for an individual do depend on their underlying 
risk of recurrence after other standard therapies. The HERA study therefore confirms 
that one year of trastuzumab remains an important, and curative, part of the standard 
of care for women with HER2-positive early breast cancer. 
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Panel: Research in context 
Systematic review 
We searched PubMed for randomised clinical trials published in English between Jan 
1, 2000, and March 1, 2013, assessing long-term outcomes (> 5 years follow-up) from 
randomised trials of systemic therapy in patients with early breast cancer confirmed 
as HER2 positive, using the search terms “adjuvant”, “breast”, “randomised” and 
“HER2”. There was no data in the literature providing 10 or more years’ follow-up from 
the use of adjuvant trastuzumab within a randomised trial. 
Added value of this study: 
 
To our knowledge, this report of the 11-year follow up of the HERA trial provides the 
longest survival data of any trial that assessed the addition of anti-HER2 therapy to 
standard treatment for HER2-positive early breast cancer. It provides long-term patient 
outcome data to support the use of 1 year of adjuvant  trastuzumab in this patient 
population, with evidence that those patients randomised to receive trastuzumab have 
sustained relative reductions in recurrence and breast-cancer deaths, with the 
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reassurance that the rate of serious toxicity is not increasing over time. It also provides 
no evidence of benefit of longer duration of trastuzumab, nor that there is any group 
studied in the HERA trial who did not derive long-term benefits. 
Implications of all the available evidence: 
Patients with early HER2-positive early breast cancer who meet the criteria for the 
HERA trial (or the other studies reported elsewhere), including the cardiac disease 
criteria, should be offered one year of adjuvant trastuzumab as part of standard of 
care. Patients can be reassured that there are benefits in terms of better disease-
free and overall survival that are sustained to at least ten years after diagnosis, with 
no evidence of significant differential benefit by disease characteristics such as nodal 
status or tumour hormone receptor status. In addition there is no evidence of late 
emergent side effects, including no evidence of more cardiac endpoints emerging 
ten years after treatment. 
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 Table 1. Demographic and Baseline Disease Characteristics of the Patients  
(Intent-to-Treat Population) 
 
Characteristic 
Observation 
(N=1697) 
1 Year of 
Trastuzumab 
(N=1702) 
2 Years of 
Trastuzumab 
(N=1700) 
Age at study entry – no. (%) 
 
 
 
          < 35 years 126 ( 7.4%) 128 ( 7.5%) 124 ( 7.3%) 
          35 – 49 years 752 (44.3%) 756 (44.4%) 756 (44.5%) 
          50 – 59 years 546 (32.2%) 546 (32.1%) 547 (32.2%) 
          >=  60 years 273 (16.1%) 272 (16.0%) 273 (16.1%) 
Previous (neo)adjuvant chemotherapy - no. (%)    
          No Anthracycline                                      99 ( 5.8%) 101 ( 5.9%) 102 ( 6.0%) 
          Anthracycline but no taxane                  1158 (68.2%) 1153 (67.7%) 1158 (68.1%) 
          Anthracycline + taxane                        440 (25.9%) 448 (26.3%) 440 (25.9%) 
Menopausal status – no. (%)1    
          Premenopausal 234 (13.8%) 258 (15.2%) 225 (13.2%) 
          Uncertain 691 (40.7%) 684 (40.2%) 686 (40.4%) 
          Postmenopausal 770 (45.4%) 760 (44.7%) 789 (46.4%) 
Pathological tumor size – no. (%)    
          Not assessed (neoadjuvant chemotherapy)          178 (10.5%) 194 (11.4%) 191 (11.2%) 
          0-2 cm      683 (40.2%) 668 (39.2%) 652 (38.4%) 
          >2-5 cm    724 (42.7%) 760 (44.7%) 741 (43.6%) 
          >5 cm  96 (5.7%) 71 (4.2%) 106 (6.2%) 
          Missing size  16 (0.9%) 9 (0.5%) 10 (0.6%) 
Nodal status – no. (%)2    
          Not assessed (neoadjuvant chemotherapy)          178 (10.5%) 194 (11.4%) 191 (11.2%) 
          Negative      555 (32.7%) 543 (31.9%)     548 (32.2%) 
          1-3 Positive nodes    490 (28.9%) 486 (28.6%) 488 (28.7%) 
          ≥ 4 Positive nodes  473 (27.9%) 479 (28.1%) 473 (27.8%) 
Hormone Receptor Status (Local) – no. (%)3    
          Positive (ER and/or PgR positive)                      855 (50.4%) 859 (50.5%) 857 (50.4%) 
          Negative (ER and PgR negative) 4                     842 (49.6%) 843 (49.5%) 843 (49.6%) 
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Footnotes for Table 1: 
1 Menopausal status at randomization 
2 One patient with missing nodal status in the observation arm 
3 One patients in the 1 year trastuzumab arm with unknown estrogen status and 
progesterone receptor-positive status 
4 This category also includes patients with ER negative and PgR unknown 
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Table 2: Site of first disease-free survival event  
 Table 2A. Site of First Disease-Free Survival Event (ITT population)1 
 
Variable 
Observation 
(N=1697) 
1 Year of 
Trastuzumab 
(N=1702) 
2 Years of 
Trastuzumab 
(N=1700) 
Number of patients with event 608 (35.8%) 505 (29.7%) 518 (30.5%) 
 
   
Local recurrence 98 ( 5.8%) 80 ( 4.7%) 78 ( 4.6%) 
Regional recurrence 29 ( 1.7%) 18 ( 1.1%) 24 ( 1.4%) 
Distant recurrence 383 (22.6%) 305 (17.9%) 291 (17.1%) 
   Central nervous system 36 ( 2.1%) 45 ( 2.6%) 32 ( 1.9%) 
   Visceral site 182 (10.7%) 127 ( 7.5%) 134 ( 7.9%) 
   Skeletal 90 ( 5.3%) 84 ( 4.9%) 78 ( 4.6%) 
   Soft tissue 75 ( 4.4%) 49 ( 2.9%) 47 ( 2.8%) 
Contralateral breast cancer2 38 ( 2.2%) 42 ( 2.5%) 45 ( 2.6%) 
Second (primary) malignancy3 40 ( 2.4%) 47 ( 2.8%) 60 ( 3.5%) 
 
   
Death, no evidence of disease 20 ( 1.2%) 13 ( 0.8%) 20 ( 1.2%) 
1In cases with multiple simultaneous sites of first event, a hierarchy assigned the event to 
the first applicable category in order: distant recurrence, regional recurrence, local 
recurrence, contralateral breast cancer, and second (primary) malignancy. 
In cases with multiple simultaneous sites of distant recurrence as first event, a hierarchy 
assigned the type of distant recurrence in order: central nervous system, visceral, skeletal, 
soft tissue. 
2Includes contralateral invasive disease and/or DCIS. There are 4 DFS events of 
contralateral DCIS which are not IDFS events under the STEEP definition. 
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3Includes second (non-breast) malignancies, invasive ipsilateral tumors of a different type 
from the primary breast cancer and ipsilateral DCIS events. The category does not include 
contralateral breast cancer of any kind. There are 8 DFS events of an ipsilateral tumour of a 
different type from the primary breast cancer which are not IDFS events under the STEEP 
definition  
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 Table 2B. Site of First Disease-Free Survival Event (hormone receptor 
positive cohort)1 
 
Variable 
Observation 
(N=855) 
1 Year of 
Trastuzumab 
(N=859) 
2 Years of 
Trastuzumab 
(N=857) 
Number of patients with event 277 (32.4%) 236 (27.5%) 252 (29.4%) 
 
   
Local recurrence 42 ( 4.9%) 35 ( 4.1%) 38 ( 4.4%) 
Regional recurrence 13 ( 1.5%) 7 ( 0.8%) 16 ( 1.9%) 
Distant recurrence 177 (20.7%) 156 (18.2%) 137 (16.0%) 
   Central nervous system 11 ( 1.3%) 21 ( 2.4%) 15 ( 1.8%) 
   Visceral site 76 ( 8.9%) 56 ( 6.5%) 50 ( 5.8%) 
   Skeletal 57 ( 6.7%) 54 ( 6.3%) 49 ( 5.7%) 
   Soft tissue 33 ( 3.9%) 25 ( 2.9%) 23 ( 2.7%) 
Contralateral breast cancer2 14 ( 1.6%) 14 ( 1.6%) 21 ( 2.5%) 
Second (primary) malignancy3 21 ( 2.5%) 18 ( 2.1%) 27 ( 3.2%) 
 
   
Death, no evidence of disease 10 ( 1.2%) 6 ( 0.7%) 13 ( 1.5%) 
1In cases with multiple simultaneous sites of first event, a hierarchy assigned the event to 
the first applicable category in order: distant recurrence, regional recurrence, local 
recurrence, contralateral breast cancer, and second (primary) malignancy. 
In cases with multiple simultaneous sites of distant recurrence as first event, a hierarchy 
assigned the type of distant recurrence in order: central nervous system, visceral, skeletal, 
soft tissue. 
2Includes contralateral invasive disease and/or DCIS. There are 2 DFS events of 
contralateral DCIS which are not IDFS events under the STEEP definition. 
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3Includes second (non-breast) malignancies, invasive ipsilateral tumors of a different type 
from the primary breast cancer and ipsilateral DCIS events. The category does not include 
contralateral breast cancer of any kind. There are 3 DFS events of an ipsilateral tumour of a 
different type from the primary breast cancer which are not IDFS events under the STEEP 
definition.  
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 Table 2C. Site of First Disease-Free Survival Event (hormone receptor 
negative cohort)1 
 
Variable 
Observation 
(N=842) 
1 Year of 
Trastuzumab 
(N=843) 
2 Years of 
Trastuzumab 
(N=843) 
Number of patients with event 331 (39.3%) 269 (31.9%) 266 (31.6%) 
 
   
Local recurrence 56 ( 6.7%) 45 ( 5.3%) 40 ( 4.7%) 
Regional recurrence 16 ( 1.9%) 11 ( 1.3%) 8 ( 0.9%) 
Distant recurrence 206 (24.5%) 149 (17.7%) 154 (18.3%) 
   Central nervous system 25 ( 3.0%) 24 ( 2.8%) 17 ( 2.0%) 
   Visceral site 106 (12.6%) 71 ( 8.4%) 84 (10.0%) 
   Skeletal 33 ( 3.9%) 30 ( 3.6%) 29 ( 3.4%) 
   Soft tissue 42 ( 5.0%) 24 ( 2.8%) 24 ( 2.8%) 
Contralateral breast cancer2 24 ( 2.9%) 28 ( 3.3%) 24 ( 2.8%) 
Second (primary) malignancy3 19 ( 2.3%) 29 ( 3.4%) 33 ( 3.9%) 
 
   
Death, no evidence of disease 10 ( 1.2%) 7 ( 0.8%) 7 ( 0.8%) 
1In cases with multiple simultaneous sites of first event, a hierarchy assigned the event to 
the first applicable category in order: distant recurrence, regional recurrence, local 
recurrence, contralateral breast cancer, and second (primary) malignancy. 
In cases with multiple simultaneous sites of distant recurrence as first event, a hierarchy 
assigned the type of distant recurrence in order: central nervous system, visceral, skeletal, 
soft tissue. 
2Includes contralateral invasive disease and/or DCIS. There are 2 DFS events of 
contralateral DCIS which are not IDFS events under the STEEP definition  
 
35 
 
3Includes second (non-breast) malignancies, invasive ipsilateral tumors of a different type 
from the primary breast cancer and ipsilateral DCIS events. The category does not include 
contralateral breast cancer of any kind. There are 5 DFS events of an ipsilateral tumour of a 
different type from the primary breast cancer which are not IDFS events under the STEEP 
definition.  
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Figure Legends 
(see separate files for figures 1, 2, 3, 4) 
 
Figure 1. CONSORT Diagram of the HERA Trial. 
 
Figure 2. Kaplan-Meier and Cumulative Incidence Plots for Disease-Free 
Survival. 
Kaplan-Meier plots of disease-free survival over time are shown for the entire ITT 
population (Panel A), for patients with hormone receptor positive disease (Panel B) 
and for patients with hormone receptor negative disease (Panel C). Cumulative 
incidence plots for breast cancer and non-breast cancer competing risks are shown 
for the entire ITT population (Panel D), for the hormone receptor positive cohort 
(Panel E) and the hormone receptor negative cohort (Panel F).  
 
Figure 3. Cumulative Incidence of Cardiac End Points. 
Competing risk analysis showing the cumulative incidence of cardiac end points with 
disease-free survival events considered as competing risks. Primary (severely 
symptomatic) cardiac endpoint (Panel A). Both primary and secondary cardiac 
endpoints (Panel B). 
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Figure 4. Hazard Ratios and Confidence Intervals Comparing 1 Year 
Trastuzumab versus Observation (Intention-to-Treat). 
Disease-free survival for the entire ITT population (Panel A), for patients with 
hormone receptor positive disease (Panel B) and for patients with hormone receptor 
negative disease (Panel C). Overall survival for the entire ITT population (Panel D), 
for the hormone receptor positive cohort (Panel E) and for the hormone receptor 
negative cohort (Panel F).  
Extended from Goldhirsch et al. (2013). These intention-to-treat analyses are 
influenced by selective crossover of 884 (52%) of patients in the observation arm 
who received trastuzumab after the first results were released in 2005. The numbers 
in parentheses show the percent of follow up time in the intention-to-treat analysis 
that was accrued after selective crossover for patients assigned to the observation 
arm. 
